Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pfizer Will Retain Infliximab Biosimilar In US After Hospira Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

While European Union requires Pfizer to divest its infliximab candidate in Europe as condition of acquisition, FTC demands only that it sell off four generics.

Advertisement

Related Content

Pfizer/Hospira's Biosimilar Pipeline: Substantial Overlap, Limited Divestiture So Far
Deal Watch: Mylan Shareholders Give Thumbs-Up To Perrigo Acquisition
Biosimilar Pathway Quickly Becoming Crowded In U.S.
FTC Approves the Pfizer-Wyeth Deal And Keeps Their Human Drug Portfolio Intact

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078852

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel